



For Immediate Release

Roche Pharma India expands partnership with Cipla to further improve access to key oncology medicines

- Roche Products (India) Pvt. Ltd. signs a distribution agreement with Cipla to expand the scope of the partnership to include, marketing and distribution of its trademark oncology drugs - Trastuzumab (Herclon), Bevacizumab (Avastin) and Rituximab (Ristova) in India

Mumbai 18th June 2020: Roche Products (India) Pvt. Ltd. (Roche Pharma) and Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") today announced that the two companies have entered into an agreement to provide better access to innovative medicines for patients in India. Under this agreement, Cipla will be responsible for marketing and distribution of Roche Pharma's key trademark oncology drugs viz., Trastuzumab (Herclon), Bevacizumab (Avastin) and Rituximab (Ristova).

Roche and Cipla had previously entered into a similar agreement in February 2018 for promotion and distribution of Tocilizumab (Actemra) and other products.

"We have been working as a partner with Cipla for some of our products and it has been a great journey working with them in ensuring access to our innovations in India. We hope to extend the same support to patients in India through this new agreement.", **said V. Simpson Emmanuel, General Manager, Roche Products (India) Pvt. Ltd.** *"This deal will ensure that our focus on providing Roche innovations in India remains steadfast in this portfolio and we will keep on collaborating with the relevant stakeholders in Indian healthcare system to ensure better outcomes for patient.."*

Commenting on the partnership, Nikhil Chopra, Executive Vice President & CEO - India Business, Cipla said, *"Enabling access to high quality life-saving treatments is core to our purpose of 'Caring for Life'. We are pleased to strengthen our partnership with Roche towards bringing innovative oncology medications to India. This represents our unwavering commitment to address the unmet needs of cancer patients through an enhanced portfolio of offerings in this space. We look forward to leveraging our solid marketing and distribution strengths in India to provide broader access to such transformative treatments in the country."*

About Roche Products (India) Pvt. Ltd.

Roche Products (India) Private Limited was incorporated in 1994 as a wholly owned subsidiary of the Roche Group, headquartered in Basel, Switzerland. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system.

For more than 60 years, Roche has been committed to making a difference to the lives of people in India. Today, Roche is the leader in oncology treatment in India; apart from cancer, Roche's has innovative medicines in other therapy areas too: transplantation, rheumatoid arthritis (RA), and chronic kidney disease (CKD)-related anaemia. Roche believes in making the latest and most innovative medicines accessible to patients in India in the fastest possible time.



For Immediate Release

Roche has been developing medicines with the goal to redefine treatment in oncology over the last 50 years. Today, Roche is investing more than ever in our effort to bring innovative treatment options that help a person's own immune system fight cancer.

For more information on Roche Pharma India, visit www.rocheindia.com

For further information, please contact:

Roche Products (India) Pvt. Ltd.

Harsh Sheth (9870631557)

harsh.sheth@roche.com

PR Agency – MSL Group

Swapnali Morajkar (9892592319)

swapnali.morajkar@mslgroup.com